- STAT+: Abivax seeks to ease safety concerns with new data, boosting sharesSafety concerns tied to Abivax's experimental bowel disease drug tanked company shares just weeks ago. But a new analysis sent them climbing.STAT · 25d ago↗ source
- STAT+: FDA’s top gene therapy regulator is leaving his roleThe departure of Vijay Kumar follows a broader leadership shakeup at the FDA.STAT · 25d ago↗ source
- STAT+: AstraZeneca to pay $34 million to settle kickback charges filed by Texas attorney generalAstraZeneca agreed to pay $34 million to settle claims that the company paid kickbacks to improperly influence prescriptions paid for by Texas Medicaid.STAT · 25d ago↗ source